To wrap up, our portfolio strategy for Week 10 remains focused on catalyst-driven alpha, balanced by tightened risk controls. We have repositioned the portfolio for upcoming inflection points.
- Continues to be a cornerstone due to the transformative potential of efzofitimod’s Phase 3 results.
- Trimmed the stake to protect gains and reduce binary risk exposure.
- High conviction: if positive, ATYR could be a game-changer (large unmet market).
- Risk management: hedged downside to ensure portfolio outperformance vs. the S&P 500 even in a negative scenario.
- Now a commercial-stage company with an FDA-approved therapy and >2 years of cash runway.
- Patiently holding unless technicals force an exit.
- Thesis: capitalize on RDEB gene therapy approval and potentially attract acquisition interest.
- Watching upcoming conference updates for launch traction.
- Along with ATYR, forms the “backbone” of the portfolio:
- ATYR → near-term catalyst.
- ABEO → medium-term commercial ramp.
- Approaching binary FDA catalyst at month’s end.
- Increased exposure: approval + PRV sale could significantly boost value.
- A calculated, event-driven risk consistent with alpha mandate.
- Already delivered on initial thesis (positive data, stock rebound).
- Now a longer-term bet on ophthalmology gene therapy.
- Strong balance sheet (~$417M cash) + fast-tracked Phase 3 trials.
- Acts as a “life jacket” in a sea of binary risks: intrinsic value + multiple shots on goal.
- Plan to hold through Q4 milestones unless fundamentals shift.
- New addition with exciting early data and tiny float.
- Small allocation = minimal risk, high upside optionality.
- Treated as an opportunistic trade (momentum play), not a long-term hold.
- Adds tactical “spice” to boost returns.
- After 9 weeks, portfolio is up ~35% vs. S&P’s ~6%.
- The coming week is crucial:
- Successful aTyr readout → potential major upside.
- Failure scenario → cuts into outperformance, but portfolio still retains substantial lead due to:
- Gains already banked.
- Diversification across catalysts and risk tiers.